Advertisment

Exploring the Role of Genetic Variation in Obesity Resistance: A New Hope in the Battle against Obesity

author-image
Mason Walker
New Update
NULL

Exploring the Role of Genetic Variation in Obesity Resistance: A New Hope in the Battle against Obesity

Advertisment

In a significant development in the fight against obesity, researchers at Weill Cornell Medicine have uncovered the potential role of a specific human genetic variant in enhancing resistance to obesity. This breakthrough preclinical study provides a new perspective on how genetic variations impact obesity susceptibility, metabolism, and response to weight loss medications.

Advertisment

Understanding the Genetic Variant

The genetic variant in question relates to the glucose-dependent insulinotropic polypeptide (GIP) receptor. This receptor interacts with a hormone released in the body in response to glucose levels after eating. Genetic variants are natural differences in DNA sequence that occur between individuals. This particular variant, the Q354 gene variant, is present in about 20 percent of individuals of European descent who carry one copy and about 5 percent who carry two copies.

The Weill Cornell Medicine team developed mice with this human genetic variant of the GIP receptor, associated with a leaner body mass index (BMI). The mice were observed to be better at processing sugar and staying leaner than mice with a different, more common variant of the receptor.

Advertisment

Implication for Metabolism and Obesity

The findings of this study suggest that people with at least one copy of this GIP receptor variant may have an altered metabolism that reduces their risk of developing obesity. This variant is believed to increase insulin production in response to glucose and the GIP hormone, potentially explaining the heightened glucose metabolism observed.

It's worth noting that these results do not automatically translate to a solution for obesity in humans. Further studies are needed to validate these findings and to explore the behavior of the receptor in other cell types.

Advertisment

Emerging Obesity Therapies and Treatments

The year 2023 has seen significant advancements in obesity therapies. Reports have highlighted the efficacy of glucagon-like peptide 1 (GLP1) mono-agonists and combinations with amylin receptor agonists. The SURMOUNT trials of the GLP1-GIP co-agonist tirzepatide have shown weight loss of up to 25% of body weight in people with obesity. Similarly, a Phase II trial with retatrutide, a GIP-GLP1-glucagon triple agonist, resulted in similar weight loss.

Looking Forward: The Potential of Genetic Research in Obesity Management

Advertisment

This study's findings add to the growing body of evidence that our genetic makeup plays a substantial role in our body's response to food, metabolism, and propensity to gain weight. Understanding these genetic variants could provide us with the tools to develop more effective weight loss medications and therapies.

Further study into the GIP receptor and other similar hormones could also shed light on other metabolic diseases. For example, research has found associations between circulating GIP and IL-1RA levels with type 2 diabetes (T2D), suggesting that these hormones could serve as early biomarkers for T2D risk.

As we continue to unravel the complex relationship between our genes, metabolism, and weight, we edge closer to a future where obesity can be more effectively managed and perhaps even prevented.

Advertisment
Chat with Dr. Medriva !